TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00937053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfusion level 120 g/dL
Description: Patients whose hemoglobin falls below 120 g/dL will be transfused with red cells within 24 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion level 70 g/dL
Description: Patients whose hemoglobin falls below 70 g/dL will be transfused with red cells within 24 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet transfusion
Description: Patients whose platelets fall below 10 x 10\*9 will be transfused with platelets

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet transfusion
Description: Patients whose platelets fall below 10 x 10\*9 will be transfused with platelets
Study: NCT01219738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single inhaled dose of placebo from a DPI.
Study: NCT03361813

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: trans-cutaneous ultrasound guided peritonsillar infiltration
Description: Preoperative peritonsillar infiltration of bupivacine in tonsillectomy surgery by using the ultrasound through a transcutaneous route

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: trans-oral ultrasound guided peritonsillar infiltration
Description: Preoperative peritonsillar infiltration of bupivacine in tonsillectomy surgery by using the ultrasound through a trans-oral route
Study: NCT00788723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) using paired-pulse technique at different interstimulus intervals (ISIs) allows the study of the excitatory and inhibitory system of human motor cortex non-invasively. Motor evoked potentials (MEP) will be recorded, and stored on a VikingSelect (Viasys Healthcare, USA). Two magnetic stimulators (Magstim 200, The Magstim Company Ltd, U.K.) connected through a Bistim and a Magstim figure-of-eight coil will be used for TMS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) using paired-pulse technique at different interstimulus intervals (ISIs) allows the study of the excitatory and inhibitory system of human motor cortex non-invasively. Motor evoked potentials (MEP) will be recorded, and stored on a VikingSelect (Viasys Healthcare, USA). Two magnetic stimulators (Magstim 200, The Magstim Company Ltd, U.K.) connected through a Bistim and a Magstim figure-of-eight coil will be used for TMS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) using paired-pulse technique at different interstimulus intervals (ISIs) allows the study of the excitatory and inhibitory system of human motor cortex non-invasively. Motor evoked potentials (MEP) will be recorded, and stored on a VikingSelect (Viasys Healthcare, USA). Two magnetic stimulators (Magstim 200, The Magstim Company Ltd, U.K.) connected through a Bistim and a Magstim figure-of-eight coil will be used for TMS.
Study: NCT00683904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL
Description: On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m\^2, intravenous (IV) solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 5 mg/min/mL, intravenous IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL
Description: After all participants in Dose Level 1 (ixabepilone, 32 mg/m\^2 + carboplatin, 5 mg/min/mL) have been observed for 1 full 21-day cycle, Dose Level 2(ixabepilone, 32 mg/m\^2 + carboplatin, 6 mg/min/mL) opened. On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m\^2, IV solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 6 mg/min/mL, IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
Study: NCT04283838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Humanistic Care
Description: Psychological and physical rehabilitation based humanistic care regimen
Study: NCT03392415

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTO PCI
Description: attempted percutaneous coronary intervention of the chronic total coronary occlusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTO PCI
Description: attempted percutaneous coronary intervention of the chronic total coronary occlusion
Study: NCT00949572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads
Description: 1 intramuscular dose (0.5 ml) on month 0, 1 and 4 containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads
Description: 1 sublingual application on month 0, 1 and 4 of 0.5 ml containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
Study: NCT03349437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitabreath Device
Description: The VitaBreath device is designed for non-continuous use only and typical device use is expected to be for 2-3 minutes. The device should only be operated for less than 10 minutes at a time. After such time, the device should be turned off for at least 30 minutes
Study: NCT02214017

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral motivation
Description: Optimization of medical care in diabetes
Study: NCT03349437

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pursed Lip Breathing
Description: Pursed lip breathing (PLB) is the standard of care and will be used as the control condition comparator.
Study: NCT03951181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEAP-MS
Description: The LEAP-MS intervention is a co-produced, digital interactive education and activity tool, specifically developed for PwPMS. The tool includes multimedia education about being active with PMS, tailored physical activity ideas and interactive functions enabling the development of personalised activity programmes, goal setting and activity logs. The digital tool works in conjunction with support from trained physiotherapists. The feasibility study will evaluate how the LEAP-MS intervention can be used in practice.
Study: NCT04568642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activate FiO2 controller
Description: Closed-loop FiO2 controller will be activated in the experimental arm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deactivate FiO2 controller
Description: Closed-loop FiO2 controller will be deactivated in the experimental arm
Study: NCT01890122

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alogliptin and Metformin FDC Placebo
Description: Alogliptin and metformin FDC placebo-matching tablets
Study: NCT01050829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadovist, BAY86-4875)
Description: Single administration at a dose of 0.1 mmol/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadopentetate Dimeglumine (Magnevist, BAY86-4882)
Description: Single administration at a dose of 0.1 mmol/kg
Study: NCT04121559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School Interventions
Description: 1. Classroom lessons on nutrition, dietary diversity, healthy food choices and handwashing.~2. Principals provide messages on nutrition, dietary diversity, healthy food choices and handwashing at flag events or school assemblies.~3. Selected adolescent girls are mentored by science teachers as peer mentors and hold weekly group discussions with other girls to discuss nutrition, dietary diversity, healthy food choices and handwashing.~4. Trained science teachers take anthropometric measurements of adolescent girls to calculate BMI and provide nutrition counseling.~5. Parent-teacher meetings to inform and encourage parents about adolescent nutrition, dietary diversity, healthy snacks, and handwashing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Interventions
Description: 1. Home visits by HEWs and/or community volunteers to discuss with parents about adolescent nutrition, dietary diversity, healthy food choices, and handwashing.~2. Community gatherings by HEWs and meetings with religious leaders to discuss with parents about adolescent nutrition, dietary diversity, healthy food choices, and handwashing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School System Interventions
Description: 1. Workshop on the adolescent nutrition interventions for school principals, science teachers, HEWs, supervisors, and woreda officers.~2. Biweekly supportive supervision on adolescent nutrition activities for schools and HEWs by school supervisors or woreda health/education office.
Study: NCT02214017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral motivation
Description: Optimization of medical care in diabetes
Study: NCT01628783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram 10 mg
Description: orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study: NCT02301104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Study: NCT02297945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metyrapone
Description: Single arm study
Study: NCT03974308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive physiotherapy including balneotherapy and filling questionaire
Description: Three-week stay in a sanatorium with comprehensive physiotherapy including balneotherapy and three time filling questionaire.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive physiotherapy without balneotherapy and filling questionaire
Description: Two-week outpatient treatment with comprehensive physiotherapy without balneotherapy and three time filling questionaire

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention, only filling questionaire
Description: No physiotherapy nor balneotherapy applied but three time filling questionaire
Study: NCT02865473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: topical instillation into the study eye
Study: NCT04599673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMNIOGEN
Description: AmnioGen® amnion matrix allograft is a bioactive tissue matrix processed from 100% human amniotic tissue. The allograft is processed with advanced technology so the graft can be suspended in liquids and applied through needles and syringes.~Amniotic tissue is composed of structural extracellular matrix, which is rich in various types of collagen, growth factors, cytokines, and specialized proteins. Thus, the application of amniotic tissue is known to modulate localized tissue inflammation, reduce scar tissue formation and promote the healing of soft tissue.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 10 ml normal saline
Study: NCT03743675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet-Induced Weight Loss
Description: Diet-Induced Weight Loss: The goal of the diet intervention is to produce a weight loss of approximately 5-10% of body weight over the six-month period, which is consistent with the goals for obesity treatment outlined by the Academy of Nutrition and Dietetics (AND). According to the 2016 AND position paper for obesity-related interventions, this level of weight loss produces clinically significant reductions in biometrics (biochemical and anthropometrics measurements) and associated risk factors for chronic disease. Additionally, obese older adults who achieve weight loss intentionally through lifestyle changes experience improved physical function. This intervention will last for 6-months with bi-weekly face-to-face counseling sessions with a registered dietitian.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet-Induced Weight Loss
Description: Diet-Induced Weight Loss: The goal of the diet intervention is to produce a weight loss of approximately 5-10% of body weight over the six-month period, which is consistent with the goals for obesity treatment outlined by the Academy of Nutrition and Dietetics (AND). According to the 2016 AND position paper for obesity-related interventions, this level of weight loss produces clinically significant reductions in biometrics (biochemical and anthropometrics measurements) and associated risk factors for chronic disease. Additionally, obese older adults who achieve weight loss intentionally through lifestyle changes experience improved physical function. This intervention will last for 6-months with bi-weekly face-to-face counseling sessions with a registered dietitian.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Exercise Intervention: Subjects will exercise on a cycle ergometer during the training sessions. Each session will consist of 1) a 5-10 minute warm up at light intensity; 2) a 20 to 30-minute training phase at moderate-to-vigorous intensity; and 3) a 5-minute cool down phase at light. The training will be conducted 3 days per week for 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Exercise Intervention: Subjects will exercise on a cycle ergometer during the training sessions. Each session will consist of 1) a 5-10 minute warm up at light intensity; 2) a 20 to 30-minute training phase at moderate-to-vigorous intensity; and 3) a 5-minute cool down phase at light. The training will be conducted 3 days per week for 6 months.
Study: NCT01055743

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical resection
Description: Radical resection of hepatocellular carcinoma

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical resection
Description: Radical resection of hepatocellular carcinoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil Implants
Description: Implanted during the surgical treatment
Study: NCT00856856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioabsorbable Everolimus Eluting Coronary Stent
Description: Bioabsorbable drug eluting stent implantation in the treatment of coronary artery disease
Study: NCT01891825

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical AF ablation
Description: Minimally invasive thoracoscopic surgical ablation of atrial fibrillation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous AF ablation
Description: Percutaneous catheter ablation of atrial fibrillation
Study: NCT03676894

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Fotona SP Dynamis
Description: Female patients with SUI will be treated with non-ablative Er:YAG laser with Fotona SP Dynamis with sham handpiece.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravaginal Fotona SP Dynamis
Description: Female patients with SUI will be treated intravaginaly with non-ablative Er:YAG laser with Fotona SP Dynamis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravaginal Fotona SP Dynamis
Description: Female patients with SUI will be treated intravaginaly with non-ablative Er:YAG laser with Fotona SP Dynamis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraurethral Fotona SP Dynamis
Description: Female patients with SUI will be treated intraurethraly with non-ablative Er:YAG laser with Fotona SP Dynamis
Study: NCT01318889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpanthenol
Description: 5% dexpanthenol Mouth wash , three times a day, 10 cc each time
Study: NCT01921348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupressure pellets
Description: The treatment group will have acupressure pellets placed in pre-determined acupressure point on the ear that relates to rhinitis.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: acupressure pellets
Description: The sham group will have acupressure pellets placed in a pre-determined non-specific acupressure point on the ear that is not related to rhinitis.
Study: NCT02431975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Standard medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medication.~The initial dose of NVP will be 6 mg per kg per dose orally twice daily until 42 weeks gestational age (2 weeks of age for infants born at term) which is the dosing selected by the NIH International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Network.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: An antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretroviral.~ZDV will be dosed as per standard guideline and routine practices.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: An antiretroviral medication used to prevent and treat HIV/AIDS. It is effective against both HIV-1 and HIV-2.~3TC will be dosed as per standard guideline and routine practices.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r
Description: Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.~LPV/r will be dosed as per standard guideline and routine practices.
Study: NCT03551652

Intervention type: DRUG
Intervention: Pharmacokinetics of rocuronium induced neuromuscular block
Description: Measurement of rocuronium induced neuromuscular block comparing patients aged \> 80 years with patients aged 18 to 50 years

Intervention type: DRUG
Intervention: Pharmacokinetics of rocuronium induced neuromuscular block
Description: Measurement of rocuronium induced neuromuscular block comparing patients aged \> 80 years with patients aged 18 to 50 years
Study: NCT04157244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored music listening intervention
Description: The music intervention consists of listening to preferred soothing music at bedtime for 30 minutes every night for four weeks (28 sessions total). This theory based caregiver-assisted intervention builds on the evidence-based protocol of using individualized music to decrease agitation in nursing home residents. It also accounts for sleep-inducing properties of music.
Study: NCT01025713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9411
Description: Inhaled GS-9411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9411
Description: Inhaled GS-9411

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled Placebo
Study: NCT00600600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: Tigecycline dosage based on age and clinical status of patient.
Study: NCT01682278

Intervention type: DEVICE
Intervention: Removal of dental amalgam restorations
Description: Patients in the amalgam cohort will have all dental amalgam restorations removed and replaced with other restorative materials used in modern dentistry. Amalgam removal will be performed by the patient's regular dentist or another dentist chosen by the patient.
Study: NCT04561570

Intervention type: DEVICE
Intervention: Vivity ACRYSOF IQ IOL Group
Description: Subjects that were implanted with the Vivity ACRYSOF IQ extended depth of focus IntaOcular Lens

Intervention type: DEVICE
Intervention: ACRYSOF IQ IOL Control Group
Description: Subject that were implanted with the ACRYSOF IQ Monofocal IntaOcular Lens
Study: NCT00681317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6280
Description: oral
Study: NCT03849170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Inoculation Technique
Description: Teaches athletes to use cognitive-behavioral techniques to reduce their stress response during sporting events.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health Intervention
Description: Will provide basic dietary and lifestyle guidelines that athletes should follow in their daily lives to maintain their health
Study: NCT02524665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAXCLARITY II (2.5% BPO) Foam Cleanser
Description: Available over the counter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAXCLARITY II (2.5% BPO) Foam Treatment
Description: Available over the counter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAXCLARITY II (0.5% Salicylic Acid) Toner Foam
Description: Available over the counter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MURAD Clarifying Cleanser (1.5% SA)
Description: Available over the counter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exfoliating Acne Treatment Gel (1% SA)
Description: Available over the counter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skin Perfecting Lotion
Description: Available over the counter.
Study: NCT04900415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Metabolic supplement for neurogenesis at the olfactory apparatus

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic portable aromatic rehabilitation (EPAR) diffuser
Description: Handheld essential oil ultrasonication diffuser technology

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic portable aromatic rehabilitation (EPAR) diffuser
Description: Handheld essential oil ultrasonication diffuser technology